Why is the TRIUMPH-3 number lower than TRIUMPH-1?

Different populations. TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease, in whom attenuated response is the expected pattern across the class.

Has retatrutide been submitted to the MHRA?

No public filing has been announced with the MHRA. The stated plan is an FDA submission in Q1 2027.

What are the maintenance trials looking at?

Whether reduction is sustained when dosing is lowered or stopped. This is the main unresolved question for incretins generally, not only for retatrutide.

Research & Regulatory News

Retatrutide TRIUMPH-2 and TRIUMPH-3: What They Added

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-223 cited sources

Eli Lilly reported TRIUMPH-2 and TRIUMPH-3 in July 2026. Both met their primary endpoints. TRIUMPH-3, in adults with severe obesity and established cardiovascular disease, reported mean weight reduction up to 22.6% at 80 weeks. Together they extend the programme beyond uncomplicated obesity into its two most clinically significant comorbid populations.

Key facts

Reported: July 2026
TRIUMPH-2 population: Obesity with type 2 diabetes
TRIUMPH-3 population: Severe obesity with established CVD
TRIUMPH-3 result: Up to 22.6% mean reduction at 80 weeks
Primary endpoints: Met in both trials
Programme enrolment: More than 5,800 participants
Planned FDA filing: Q1 2027

Why these two trials matter more than the headline number

TRIUMPH-1 answered how much weight reduction is achievable in a relatively uncomplicated obesity population. That is the easier question. TRIUMPH-2 and TRIUMPH-3 ask whether the same compound performs in people who actually carry the conditions that make obesity dangerous — type 2 diabetes in one case, established cardiovascular disease in the other. Regulators and payers weight these populations heavily, because they are where the clinical benefit has to be demonstrated.

TRIUMPH-3 and the cardiovascular population

In adults with severe obesity and established cardiovascular disease, mean reduction reached up to 22.6% at 80 weeks. The figure is lower than TRIUMPH-1's 28.3%, which is expected: this is an older, sicker population with more concomitant medication and different tolerability constraints. That it met its primary endpoint in this group is the substantive finding.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

TRIUMPH-2 and glycaemic control

The type 2 diabetes study reported improvements in both body weight and A1C. Weight reduction in diabetic populations is typically attenuated compared with non-diabetic ones across the entire incretin class, so comparisons should be made within population rather than against the TRIUMPH-1 headline.

What is still outstanding

Seven further Phase 3 readouts were expected across 2026, including studies of maintenance dosing strategies — that is, what happens when the dose is reduced or stopped after the initial reduction phase. Weight regain after discontinuation is the open question across the whole incretin class, and maintenance data are what the field is actually waiting on.

Regulatory position

Positive pivotal data do not confer authorisation. Retatrutide remains investigational in every jurisdiction, including the UK. Lilly has indicated an intended Biologics License Application to the FDA in the first quarter of 2027; MHRA and EMA timelines have not been stated publicly.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why is the TRIUMPH-3 number lower than TRIUMPH-1?: Different populations. TRIUMPH-3 enrolled adults with severe obesity and established cardiovascular disease, in whom attenuated response is the expected pattern across the class.
Has retatrutide been submitted to the MHRA?: No public filing has been announced with the MHRA. The stated plan is an FDA submission in Q1 2027.
What are the maintenance trials looking at?: Whether reduction is sustained when dosing is lowered or stopped. This is the main unresolved question for incretins generally, not only for retatrutide.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum